Aurobindo Pharma to acquire 60% stake in Celon Laboratories’ manufacturing facility

12 Aug 2013 Evaluate

Aurobindo Pharma has received its board’s approval to acquire 60% of an upcoming manufacturing facility (under construction) being established by Celon Laboratories to manufacture Hormonal and Oncology products for a total cash consideration of Rs 15.60 crore and also approved to further invest towards completion and approval of the facility including new product developments in above therapeutic areas with budgeted investment outlay of Rs 32.30 crore over next 12 months

Meanwhile, the company’s board has decided to acquire 57% of the equity stake in Silicon Life Sciences Private, a company engaged in manufacture of non-sterile penems, from its existing shareholders of 49% from VVR group and 8% from Trident Chemphar. Post this acquisition, the equity holding of the company would increase to 75%, thereby making Silicon a subsidiary of the company.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1213.90 -3.55 (-0.29%)
08-Dec-2025 09:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1796.25
Dr. Reddys Lab 1274.40
Cipla 1512.50
Zydus Lifesciences 934.40
Lupin 2094.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×